Akari Therapeutics
AKTX
10 hedge funds and large institutions have $5.25M invested in Akari Therapeutics in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
36% more capital invested
Capital invested by funds: $3.88M → $5.25M (+$1.38M)
0% more funds holding
Funds holding: 10 → 10 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$315K |
| 2 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$67.8K |
| 3 |
TC
Truvestments Capital
Sarasota,
Florida
|
+$8.07K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$3.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$115K |
| 2 |
VF
Virtu Financial
New York
|
-$58K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$32.3K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$30.7K |
| 5 |
Millennium Management
New York
|
-$16.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
Hikari Power
Tokyo,
Japan
| $2.56M | +$315K | +195 | +18% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $1.16M | – | – | – |
|
|
VC
3
Vivo Capital
Palo Alto,
California
| $885K | – | – | – |
|
|
ECM
4
Endurant Capital Management
San Mateo,
California
| $419K | -$32.3K | -20 | -9% |
|
|
AAMU
5
Amundi Asset Management US
Boston,
Massachusetts
| $86K | +$67.8K | +42 | New |
|
|
6
Millennium Management
New York
| $70K | -$16.1K | -10 | -23% |
|
|
7
Bank of Montreal
Toronto,
Ontario, Canada
| $38K | -$30.7K | -19 | -50% |
|
8
Parallax Volatility Advisers
San Francisco,
California
| $19K | – | – | – |
|
|
TC
9
Truvestments Capital
Sarasota,
Florida
| $11K | +$8.07K | +5 | New |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $4K | +$3.23K | +2 | New |
|
11
Morgan Stanley
New York
| $1K | – | – | – |
|
|
BBA
12
Baker Bros. Advisors
New York
| – | -$115K | -73 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$58K | -37 | Closed |
|
14
UBS Group
Zurich,
Switzerland
| – | -$5K | -4 | Closed |
|
AKTX Hedge Fund Activity: Q3 2018 in Review
10 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2018, worth a combined $5.25M — up 36% from $3.88M a quarter earlier.
Fund positioning in AKTX was balanced in Q3 2018: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Hikari Power, adding an estimated $315K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $115K sold.
- 10 institutional investors held Akari Therapeutics (AKTX) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $5.25M of Akari Therapeutics stock for Q3 2018, up 36% quarter-over-quarter.
- 3 funds opened new Akari Therapeutics positions in Q3 2018 and 3 closed out, a net change of 0 holders.
- The largest Akari Therapeutics buyer in Q3 2018 was Hikari Power, an estimated $315K added.
- The largest Akari Therapeutics seller in Q3 2018 was Baker Bros. Advisors, an estimated $115K sold.
Based on aggregated 13F filings for Q3 2018.